BRPI0616976A2 - composições lìquidas iÈnicas multi-funcionais para superar polimorfismos e conferir propriedades a ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos - Google Patents

composições lìquidas iÈnicas multi-funcionais para superar polimorfismos e conferir propriedades a ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos

Info

Publication number
BRPI0616976A2
BRPI0616976A2 BRPI0616976-7A BRPI0616976A BRPI0616976A2 BR PI0616976 A2 BRPI0616976 A2 BR PI0616976A2 BR PI0616976 A BRPI0616976 A BR PI0616976A BR PI0616976 A2 BRPI0616976 A2 BR PI0616976A2
Authority
BR
Brazil
Prior art keywords
overcome
polymorphisms
nutritional
biological
ionic liquid
Prior art date
Application number
BRPI0616976-7A
Other languages
English (en)
Inventor
Daniel T Daly
Richard P Swatloski
Whitney L Hough
James Hillard Davis
Marcim Smiglak
Juliusz Pernak
Scott K Spear
Robin D Rogers
Original Assignee
Univ Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama filed Critical Univ Alabama
Publication of BRPI0616976A2 publication Critical patent/BRPI0616976A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

COMPOSIçõES LìQUIDAS IÈNICAS MULTI-FUNCIONAIS PARA SUPERAR POLIMORFISMOS E CONFERIR PROPRIEDADES A INGREDIENTES ATIVOS FARMACêUTICOS, BIOLóGICOS, NUTRICIONAIS E ENERGéTICOS. São revelados líquidos iónicos e métodos de preparação de composições de líquido jónico de ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos. São também revelados métodos de utilização das composições aqui reveladas para superar polimorfismos, superar problemas de solubilidade e distribuição, controlar taxas de liberação, adicionar funcionalidades, aumentar a eficácia (sinergia), e melhorar a facilidade do uso e da fabricação.
BRPI0616976-7A 2005-10-07 2006-10-10 composições lìquidas iÈnicas multi-funcionais para superar polimorfismos e conferir propriedades a ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos BRPI0616976A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72460405P 2005-10-07 2005-10-07
US72460505P 2005-10-07 2005-10-07
US76485006P 2006-02-02 2006-02-02
PCT/US2006/039454 WO2007044693A2 (en) 2005-10-07 2006-10-10 Multi-functional ionic liquid compositions

Publications (1)

Publication Number Publication Date
BRPI0616976A2 true BRPI0616976A2 (pt) 2009-11-24

Family

ID=37943465

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616976-7A BRPI0616976A2 (pt) 2005-10-07 2006-10-10 composições lìquidas iÈnicas multi-funcionais para superar polimorfismos e conferir propriedades a ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos

Country Status (11)

Country Link
US (2) US8232265B2 (pt)
EP (1) EP1931760A4 (pt)
JP (3) JP5713534B2 (pt)
KR (2) KR20080068679A (pt)
CN (2) CN101326275B (pt)
AU (2) AU2006302237C1 (pt)
BR (1) BRPI0616976A2 (pt)
CA (2) CA2867194C (pt)
IL (1) IL190646A (pt)
MX (1) MX343314B (pt)
WO (1) WO2007044693A2 (pt)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014007725B1 (pt) 2004-03-10 2016-10-11 Monsanto Technology Llc método de matar ou controlar ervas daninhas ou plantas indesejadas compreendendo aplicação de composição de concentrado herbicida aquoso de glifosato
CN100496246C (zh) * 2004-06-07 2009-06-10 辛根塔参与股份公司 减轻线虫损害的方法
CA2867194C (en) 2005-10-07 2016-10-04 The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
WO2007136873A2 (en) * 2006-05-19 2007-11-29 The Procter & Gamble Company Process for decarboxylation of fatty acids and oils to produce paraffins or olefins
JP5360751B2 (ja) * 2007-01-29 2013-12-04 株式会社 メドレックス 非ステロイド系抗炎症薬と有機アミン化合物との塩とその用途
US8148518B2 (en) 2007-02-14 2012-04-03 Eastman Chemical Company Cellulose esters and their production in carboxylated ionic liquids
US9834516B2 (en) * 2007-02-14 2017-12-05 Eastman Chemical Company Regioselectively substituted cellulose esters produced in a carboxylated ionic liquid process and products produced therefrom
US10174129B2 (en) 2007-02-14 2019-01-08 Eastman Chemical Company Regioselectively substituted cellulose esters produced in a carboxylated ionic liquid process and products produced therefrom
MX2009008934A (es) * 2007-02-26 2009-08-28 Dow Agrosciences Llc Proceso para la preparacion de algunas sulfiliminas sustituidas.
US20100020280A1 (en) * 2007-03-16 2010-01-28 Pathogen Dection Systems, Inc. d/b/a Pathogen Systems, Inc. Method for aligning liquid crystals
EP2170400B1 (en) * 2007-07-10 2012-07-25 Medy-Tox, INC. Pharmaceutical liquid composition of botulinum toxin with improved stability
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
US8067632B2 (en) * 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
EP2033945A1 (en) * 2007-09-06 2009-03-11 Infineum International Limited Quaternary ammonium salts
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
DE102007053664A1 (de) * 2007-11-08 2009-05-14 Friedrich-Schiller-Universität Jena Optische Sensoren zur Detektion von Ionen, Gasen und Biomolekülen sowie Verfahren zu deren Herstellung und Verwendung
CA2714065A1 (en) * 2008-02-05 2009-08-13 Arysta Lifescience North America, Llc Solid formulation of low melting active compound
US8158777B2 (en) 2008-02-13 2012-04-17 Eastman Chemical Company Cellulose esters and their production in halogenated ionic liquids
US8188267B2 (en) * 2008-02-13 2012-05-29 Eastman Chemical Company Treatment of cellulose esters
US8354525B2 (en) * 2008-02-13 2013-01-15 Eastman Chemical Company Regioselectively substituted cellulose esters produced in a halogenated ionic liquid process and products produced therefrom
US9777074B2 (en) 2008-02-13 2017-10-03 Eastman Chemical Company Regioselectively substituted cellulose esters produced in a halogenated ionic liquid process and products produced therefrom
EP2939538B1 (en) 2008-07-03 2018-11-14 Monsanto Technology LLC Combinations of derivatized saccharide surfactants and etheramine oxide surfactants as herbicide adjuvants
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
WO2010078258A1 (en) * 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Compounds comprising two or more biologically functional ions and method of treating parkinson's disease
WO2010078300A1 (en) * 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
US8524887B2 (en) * 2009-04-15 2013-09-03 Eastman Chemical Company Regioselectively substituted cellulose esters produced in a tetraalkylammonium alkylphosphate ionic liquid process and products produced therefrom
US9096743B2 (en) 2009-06-01 2015-08-04 The Board Of Trustees Of The University Of Alabama Process for forming films, fibers, and beads from chitinous biomass
JP5940448B2 (ja) 2009-07-10 2016-06-29 リンジー オー． ザ サード スコット， 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
WO2011019652A2 (en) 2009-08-10 2011-02-17 Monsanto Technology Llc Low volatility auxin herbicide formulations
CN101627767B (zh) * 2009-08-18 2013-03-20 深圳诺普信农化股份有限公司 一种含有虱螨脲的水乳剂及其制备方法
US9951008B2 (en) 2009-11-03 2018-04-24 University Of Notre Dame Du Lac Ionic liquids comprising heteraromatic anions
US9289381B2 (en) 2009-12-03 2016-03-22 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
WO2011110662A1 (en) 2010-03-11 2011-09-15 Danmarks Tekniske Universitet Supported biologically active compounds
CN101851267A (zh) * 2010-04-22 2010-10-06 江南大学 一种抗体保护剂及其应用
US20130109572A1 (en) * 2010-07-06 2013-05-02 The Board Of Trustees Of The University Of Alabama Herbicidal compositions and methods of use
US20130217735A1 (en) * 2010-08-12 2013-08-22 Agri-Food And Biosciences Institute Fungicidal compositions and methods of use
KR101319420B1 (ko) * 2011-03-18 2013-10-17 한남대학교 산학협력단 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템
US9394375B2 (en) 2011-03-25 2016-07-19 Board Of Trustees Of The University Of Alabama Compositions containing recyclable ionic liquids for use in biomass processing
WO2012135178A1 (en) 2011-03-28 2012-10-04 The Board Of Trustees Of The University Of Alabama N-functionalized imidazole-containing systems and methods of use
US8729253B2 (en) 2011-04-13 2014-05-20 Eastman Chemical Company Cellulose ester optical films
WO2013005226A1 (en) 2011-07-04 2013-01-10 Zota Health Care Ltd A novel combined pharmaceutical composition containing diclofenac and methods of making and using the same
WO2013030299A1 (en) 2011-08-31 2013-03-07 Danmarks Tekniske Universitet Method for enhancing the thermal stability of ionic compounds
BR122019001001B1 (pt) 2011-10-26 2019-08-27 Monsanto Technology Llc sais herbicidas de auxina, mistura de aplicação herbicida compreendendo os mesmos para uso na eliminação e controle do crescimento de plantas indesejadas, bem como métodos de controle de plantas indesejadas e de plantas suscetíveis ao herbicida de auxina
US8673956B2 (en) 2011-12-02 2014-03-18 Board Of Trustees Of The University Of Alabama Imido-acid salts and methods of use
KR101995612B1 (ko) 2012-03-14 2019-07-02 가부시키가이샤 엘티티 바이오파마 만성 폐색성 폐질환 개선제
US20130252945A1 (en) * 2012-03-23 2013-09-26 Los Alamos National Security, Llc Amorphous bioinorganic ionic liquid compositions comprising pharmaceuticals
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CN102697779B (zh) * 2012-06-01 2014-11-05 康阳润和（北京）医药科技有限公司 高溶散速率的伊来西胺药物组合物及其制法
WO2013184622A2 (en) 2012-06-04 2013-12-12 Monsanto Technology Llc Aqueous concentrated herbicidal compositions containing glyphosate salts and dicamba salts
WO2014071348A1 (en) 2012-11-05 2014-05-08 Monsanto Technology Llc Auxin herbicidal mixtures
US20140155625A1 (en) * 2012-11-30 2014-06-05 Xerox Corporation Modified Naturally-Derived Colorants For Phase Change Ink Applications
DK2961276T3 (en) 2013-02-27 2018-11-19 Monsanto Technology Llc Glyphosate and dicamba tank mixtures with improved volatility
US9096480B2 (en) 2013-06-28 2015-08-04 Uop Llc Catalytic disproportionation of heptane using ionic liquids
US9102577B2 (en) 2013-06-28 2015-08-11 Uop Llc Catalytic disproportionation of paraffins using ionic liquids
US9126881B2 (en) 2013-06-28 2015-09-08 Uop Llc Catalytic isomerization of pentane using ionic liquids
US20150005555A1 (en) 2013-06-28 2015-01-01 Uop Llc Catalytic disproportionation of butane using ionic liquids
US9096482B2 (en) 2013-06-28 2015-08-04 Uop Llc Catalytic reverse disproportionation of paraffins using ionic liquids
US9102578B2 (en) 2013-06-28 2015-08-11 Uop Llc Catalytic isomerization of paraffins using ionic liquids
US9096483B2 (en) 2013-06-28 2015-08-04 Uop Llc Catalytic isomerization of hexanes using ionic liquids
US9096485B2 (en) 2013-06-28 2015-08-04 Uop Llc Catalytic isomerization of heptane using ionic liquids
US9096481B2 (en) 2013-06-28 2015-08-04 Uop Llc Catalytic disproportionation of pentane using ionic liquids
GB201313423D0 (en) 2013-07-26 2013-09-11 Innospec Ltd Compositions and methods
WO2015013772A1 (en) * 2013-08-01 2015-02-05 Monash University Compositions and preparation methods of low melting ionic salts of poorly- water soluble drugs
CN103417546B (zh) * 2013-08-19 2016-01-27 中国人民解放军军事医学科学院基础医学研究所 亚甲蓝的一种麻醉后促清醒的用途
CA2924069C (en) 2013-09-11 2021-11-02 Arsia Therapeutics, Inc. Liquid protein formulations containing ionic liquids
US20150080468A1 (en) * 2013-09-13 2015-03-19 Quality Liquid Feeds Composition and method for processing and delivering bioavailable methionine analogs, derivatives, and precursors, thereof
CN103529146A (zh) * 2013-10-10 2014-01-22 中国热带农业科学院分析测试中心 采用离子液体提取鸡肉中磺胺类药物残留的方法
WO2015054887A1 (zh) * 2013-10-18 2015-04-23 浙江省诸暨合力化学对外贸易有限公司 三酮类铵盐化合物及其制备方法及应用
CN103626588B (zh) * 2013-12-03 2016-07-06 广西新方向化学工业有限公司 一种糖醇脲有机叶面肥
US9765196B2 (en) 2014-02-20 2017-09-19 Rutgers, The State University Of New Jersey Inorganic ionomers made from minerals
US9958363B2 (en) * 2014-06-23 2018-05-01 Agilent Technologies, Inc. Fluorous affinity extraction for ionic liquid-based sample preparation
GB201413355D0 (en) * 2014-07-28 2014-09-10 Innospec Ltd Compositons and methods
US10100131B2 (en) 2014-08-27 2018-10-16 The Board Of Trustees Of The University Of Alabama Chemical pulping of chitinous biomass for chitin
EP3197989A1 (en) * 2014-09-25 2017-08-02 The Procter and Gamble Company Ionic liquids
CN106999510B (zh) 2014-10-01 2021-04-30 伊格尔生物制品有限公司 含有粘度降低剂的多糖和核酸制剂
US10982381B2 (en) 2014-10-06 2021-04-20 Natural Fiber Welding, Inc. Methods, processes, and apparatuses for producing welded substrates
US10011931B2 (en) 2014-10-06 2018-07-03 Natural Fiber Welding, Inc. Methods, processes, and apparatuses for producing dyed and welded substrates
US10039758B2 (en) 2014-10-24 2018-08-07 Keck Graduate Institute Of Applied Life Sciences Compositions and methods for inhibiting bacterial and viral pathogens
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN104860940B (zh) * 2015-05-22 2017-05-10 湖南省中医药研究院中药研究所 丙戊酸原小檗碱类化合物、制备方法和用途
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
JP6546031B2 (ja) * 2015-08-06 2019-07-17 デクセリアルズ株式会社 イオン液体、潤滑剤及び磁気記録媒体
CN105388243B (zh) * 2015-12-09 2017-01-11 中国检验检疫科学研究院 一种化妆品中己脒定和氯己定及其盐类的测定方法
CN105623307B (zh) * 2015-12-21 2017-08-08 无锡科莱欣机电制造有限公司 蓝色环保型纺织染料混合物
US10357762B2 (en) 2016-01-26 2019-07-23 The Board Of Trustees Of The University Of Alabama Mixed metal double salt ionic liquids with tunable acidity
CN109072542B (zh) 2016-03-25 2022-03-08 天然纤维焊接股份有限公司 用于生产焊接基质的方法、工艺和设备
CA3021729A1 (en) 2016-05-03 2017-11-09 Natural Fiber Welding, Inc. Methods, processes, and apparatuses for producing dyed and welded substrates
CN106265697A (zh) * 2016-08-16 2017-01-04 武汉软件工程职业学院 水杨酸混合物及其制备方法、水杨酸离子液体溶液及离子液体的用途
JP6816431B2 (ja) * 2016-09-29 2021-01-20 東レ株式会社 イオン塩、それを含有する熱可塑性樹脂組成物およびその製造方法
US10927191B2 (en) 2017-01-06 2021-02-23 The Board Of Trustees Of The University Of Alabama Coagulation of chitin from ionic liquid solutions using kosmotropic salts
EP3586842A4 (en) * 2017-02-27 2021-04-14 Seed Research Institute Co., Ltd. ANTIFUNGAL COMPOSITION
WO2018236445A2 (en) 2017-03-24 2018-12-27 The Board Of Trustees Of The University Of Alabama METALLIC-CHITIN PARTICLE COMPOSITE MATERIALS AND METHODS OF MAKING SAME
WO2018222924A1 (en) * 2017-06-01 2018-12-06 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN107501327B (zh) * 2017-07-20 2019-07-05 暨明医药科技（苏州）有限公司 环磷酰胺—水物的结晶方法
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
WO2019099837A1 (en) * 2017-11-17 2019-05-23 President And Fellows Of Harvard College Ionic liquids for internal delivery
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
CN109173956B (zh) * 2018-03-01 2020-05-26 中国石油大学(北京) 处理氯铝酸类离子液体废催化剂和碱性废水的系统
CN110386869A (zh) * 2018-04-20 2019-10-29 华东理工大学 布洛芬离子液体及其制备方法
CN110496115B (zh) * 2018-05-18 2022-10-25 华东理工大学 二甲双胍离子液体及其制备和应用
ES2963675T3 (es) * 2018-07-11 2024-04-01 Fine Agrochemicals Ltd Concentrado regulador del crecimiento de plantas y uso del mismo
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
WO2020028684A1 (en) * 2018-08-01 2020-02-06 Jumpstart Fertility Pty Ltd Salts of nicotinic acid and nicotinamide as anti-aging agents
CN109187948B (zh) * 2018-08-17 2021-10-29 郑州大学 一种洛克沙胂和硝苯胂酸双联检测试纸
CN109211862B (zh) * 2018-10-23 2021-03-30 山西大学 一种红色荧光铜纳米团簇探针的制备方法及其应用
RU2749902C2 (ru) * 2018-10-31 2021-06-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний
CN111825742B (zh) * 2019-04-18 2024-01-30 陈铭 Ctpa作为特种偶合剂用于氨基酸离子液体的多肽固相合成
CN110064396B (zh) * 2019-04-25 2020-05-01 山东大学 基于还原性离子液体的富含氧空位的三氧化二铁固氮催化剂、制备方法及其电催化固氮应用
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN110881481B (zh) * 2019-10-30 2021-04-06 广州市浪奇实业股份有限公司 一种含有大麻叶提取物的抗菌组合物及其应用
CN112755196B (zh) * 2019-11-01 2024-02-27 华东理工大学 多奈哌齐离子液体
CN110894207B (zh) * 2019-11-21 2023-03-31 宁夏泰益欣生物科技股份有限公司 一种盐酸克林霉素棕榈酸酯的纯化方法
CN112909328A (zh) * 2019-12-04 2021-06-04 中国科学院宁波材料技术与工程研究所 一种超薄硫化物固体电解质层及其制备方法和应用
KR102102402B1 (ko) * 2019-12-05 2020-04-20 유은옥 고형 화장비누 제조방법
CN111272717B (zh) * 2020-02-10 2024-02-27 河南师范大学 基于离子液体新型荧光碳点的一步水热合成及其对磺胺噻唑的检测应用
CN111302930B (zh) * 2020-03-12 2023-11-07 湖南复瑞生物医药技术有限责任公司 一种对苯丁氧基苯甲酸的制备方法
CN111253289A (zh) * 2020-03-27 2020-06-09 湖南吴赣药业有限公司 一种磺胺醋酰钠的合成方法
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112089823B (zh) * 2020-09-25 2024-02-06 珠海中科先进技术研究院有限公司 一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂
BR102020026974A2 (pt) * 2020-12-29 2022-07-12 Universidade Estadual De Campinas - Unicamp Processo de obtenção de composições nutracêuticas e composições nutracêuticas assim obtidas
CN112674106B (zh) * 2021-01-06 2021-12-07 沈阳农业大学 一种可溶液剂及其制备方法
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
CN113788788B (zh) * 2021-07-23 2023-12-05 浙江工业大学 一种荧光离子液体及其合成方法与应用
CN114539336B (zh) * 2022-01-24 2023-06-30 河北圣雪大成制药有限责任公司 一种阿维拉霉素a的提纯方法
CN114642733B (zh) * 2022-03-02 2023-08-22 中山大学 一种治疗雄激素源性脱发的组合物及其制备方法
CN116407557A (zh) * 2023-05-29 2023-07-11 四川大学华西医院 一种防治出血性脑卒中的药物组合物及其应用
CN116622514B (zh) * 2023-07-21 2023-10-20 南京师范大学 提高微生物菌体和/或微生物油脂中多不饱和脂肪酸含量的调控方法及应用
CN117643551B (zh) * 2024-01-30 2024-03-29 广州悦瑞化妆品有限公司 一种多肽次抛精华及其制备方法

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1943176A (en) 1930-09-27 1934-01-09 Chem Ind Basel Cellulose solution
US2004891A (en) * 1931-12-08 1935-06-11 Novocol Chemical Mfg Co Inc Anaesthetic composition
GB869149A (en) 1958-09-16 1961-05-31 Clinical Products Ltd Liquid pharmaceutical compositions comprising compounds of ion exchange resins and therapeutic substances
US3344018A (en) 1961-10-27 1967-09-26 Hollichem Corp Biocidal quaternary ammonium sulfamates
US3223704A (en) 1961-10-27 1965-12-14 Hollichem Corp Quaternary ammonium sulfamates
NL302478A (pt) 1962-12-24
DE1443879C3 (de) 1964-02-21 1974-07-25 Bayer Ag, 5090 Leverkusen Ungesättigte quartäre Ammoniumverbindungen und Verfahren zu deren Herstellung
GB1067094A (en) 1964-05-12 1967-05-03 Hollichem Corp Quaternary ammonium sulfamates
FR1404697A (fr) 1964-06-09 1965-07-02 Hollichem Corp Nouveaux sulfamates d'ammonium quaternaire
US3471423A (en) 1966-11-07 1969-10-07 Gen Tire & Rubber Co Polyurethane materials having biocidal properties and their production
US4104368A (en) 1970-05-11 1978-08-01 Millmaster Onyx Corporation Composition and method for protecting skin and hair
US4001394A (en) 1974-01-30 1977-01-04 American Cyanamid Company Shampoo creme rinse containing a quaternary ammonium saccharinate, cyclamate or phthalimidate
US4097666A (en) 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
DE2703703A1 (de) 1977-01-29 1978-08-03 Dynamit Nobel Ag Traegergebundene acylasen
DE2737118A1 (de) 1977-08-17 1979-03-01 Projektierung Chem Verfahrenst Verfahren zur gewinnung von zuckern, gegebenenfalls cellulose und gegebenenfalls lignin aus lignocellulosischen pflanzlichen rohstoffen
US4171352A (en) * 1977-08-22 1979-10-16 Polysciences, Inc. Quantitative evaluation of enteric microbial overgrowth
US4228162A (en) 1979-07-09 1980-10-14 Research Corporation Dimethyl isosorbide in liquid formulation of aspirin
US4224319A (en) 1979-07-31 1980-09-23 Ernest Marcadet Antiseptic composition for topical application to the skin
DE3267656D1 (en) 1981-04-24 1986-01-09 Ciba Geigy Ag Herbicidal agents
US4421547A (en) * 1982-04-06 1983-12-20 Stauffer Chemical Company 4-Hydroxy-5-isopropyl-2-methylphenyl trimethylammonium, 1-piperidine carboxylate salt of N-phosphonomethylglycine and its use as a herbicide
US4491574A (en) 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
ES521561A0 (es) 1983-04-18 1984-08-01 Lacer Sa Procedimiento para la obtencion de amonios cuaternarios insolubles
CA1242748A (en) 1984-11-26 1988-10-04 Rita S. Jones Salt of dicamba
US4761164A (en) 1985-03-01 1988-08-02 Air Products And Chemicals, Inc. Method for gas separation
JPS61236818A (ja) 1985-04-15 1986-10-22 Masako Matsumoto エポキシ樹脂硬化剤
JPS62198609A (ja) 1986-02-26 1987-09-02 Toray Ind Inc 化粧品又は医薬部外品配合用粒子
JPS6356501A (ja) 1986-08-26 1988-03-11 Chisso Corp アフイニテイークロマトグラフイー用カラム充填剤及びその製造方法
NZ226377A (en) 1988-09-28 1992-06-25 Nigel Paul Maynard Water-insoluble biocidal or preservative composition comprising a borate organic complex ion and a biocidally active cationic species
US4973456A (en) 1988-10-24 1990-11-27 Air Products And Chemicals, Inc. Use of salt hydrates as reversible absorbents of acid gases
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
DK0518976T3 (da) 1990-03-06 1996-10-14 David Tate Fungicide sammensætninger til anvendelse på planter
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
FR2735658B1 (fr) 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
US5246716A (en) 1992-01-10 1993-09-21 W. Neudorff Gmbh Kg Fatty acid-based antifungal composition having residual activity
US5428000A (en) 1992-06-26 1995-06-27 Toho Chemical Industry Co., Ltd. Antagonism inhibitors for herbicides, herbicide compositions and herbicidal methods
DE4308410A1 (de) 1993-03-12 1994-09-15 Schering Ag Verfahren zur Synthese und Selektionierung von Sequenzen aus kovalent verbundenen Bausteinen
AT399519B (de) 1993-09-14 1995-05-26 Chemiefaser Lenzing Ag Form- bzw. spinnmasse enthaltend cellulose und verfahren zur herstellung cellulosischer formkörper
GB9402612D0 (en) 1994-02-10 1994-04-06 British Petroleum Co Plc Ionic liquids
CN1123031A (zh) 1994-02-10 1996-05-22 英国石油化学品有限公司 离子液体
GB9402569D0 (en) 1994-02-10 1994-04-06 Bp Chem Int Ltd Alkylation process
SK282009B6 (sk) 1994-08-31 2001-10-08 J. M. Huber Corporation Zubný prostriedok, hlinitokremičitan sodný a spôsob jeho prípravy
US5792399A (en) 1994-11-03 1998-08-11 Ostthuringische Materialprufgesellschaft Fur Textil Und Kunststoffe Mbh Formed shape made of regenerated cellulose and process for its production
DE69534293T2 (de) 1994-12-21 2006-05-18 Centre National De La Recherche Scientifique (C.N.R.S.) Flüssige, hydrophobe Salze, ihre Herstellung und ihre Verwendung in der Elektrochemie
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5827602A (en) 1995-06-30 1998-10-27 Covalent Associates Incorporated Hydrophobic ionic liquids
CA2176515C (en) 1996-05-14 1996-10-22 Eckhard H. Biller Fire suppressant foam, dispersant and detergent eckhard iii - formula
JP3019776B2 (ja) 1996-07-04 2000-03-13 三菱化学株式会社 Ｎ−アルキル−ｎ′−メチルイミダゾリニウム有機酸塩の製造方法
US5731101A (en) 1996-07-22 1998-03-24 Akzo Nobel Nv Low temperature ionic liquids
ATE221770T1 (de) 1997-05-14 2002-08-15 Galen Chemicals Ltd Topische mittel
US20020010291A1 (en) 1998-12-04 2002-01-24 Vince Murphy Ionic liquids and processes for production of high molecular weight polyisoolefins
DE19919494A1 (de) 1999-04-29 2000-11-02 Celanese Chem Europe Gmbh Ionische Flüssigkeiten, ihre Herstellung und ihre Verwendung
GB9919558D0 (en) * 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
GB9928290D0 (en) 1999-12-01 2000-01-26 Univ Belfast Process for preparing ambient temperature ionic liquids
GB0008707D0 (en) 2000-04-07 2000-05-31 Bp Chem Int Ltd Imidazole carbenes
DE10022987A1 (de) * 2000-05-11 2001-11-22 Aventis Cropscience Gmbh Kombinationen von Pflanzenschutzmitteln mit kationischen Polymeren
ATE266008T1 (de) 2000-10-27 2004-05-15 Centre Nat Rech Scient Imidazolium-salze und die verwendung dieser ionischen flüssigkeiten als lösungsmittel und als katalysator
DE10063960A1 (de) 2000-12-20 2002-06-27 Aventis Cropscience Gmbh Herbizide Mittel
US6924341B2 (en) * 2001-03-30 2005-08-02 The Uab Research Foundation Polymer formation in room temperature ionic liquids
GB2374082A (en) * 2001-04-04 2002-10-09 Procter & Gamble Particles for a detergent product
US6846926B1 (en) * 2001-06-06 2005-01-25 The United States Of America As Represented By The Secretary Of The Navy Triazolyl-aminotriazine compositions, including salts
DE10130298A1 (de) 2001-06-22 2003-01-23 Nutrinova Gmbh Antimikrobiell wirksame Acesulfam-Komplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
US6803345B2 (en) 2001-09-26 2004-10-12 Platte Chemical Co. Herbicide microemulsion-forming-concentrates, microemulsions, and methods
US6824599B2 (en) 2001-10-03 2004-11-30 The University Of Alabama Dissolution and processing of cellulose using ionic liquids
US6808557B2 (en) 2001-10-03 2004-10-26 The University Of Alabama Cellulose matrix encapsulation and method
DE60314495T2 (de) 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
US20040007693A1 (en) 2002-07-03 2004-01-15 Roger Moulton Ionic liquids containing borate or phosphate anions
AU2003262999B2 (en) * 2002-08-31 2009-07-23 Monsanto Technology Llc Pesticide compositions containing dicarboxylic acids
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
CN1235479C (zh) * 2002-11-28 2006-01-11 四川贝尔实业有限责任公司 草甘膦异丙胺盐水剂的制备方法
RU2342953C2 (ru) 2003-02-24 2009-01-10 Фармасьютикал Продакшенз, Инк. Трансмукозная система доставки лекарственных средств
US7114146B2 (en) * 2003-05-02 2006-09-26 International Business Machines Corporation System and method of dynamic service composition for business process outsourcing
US7572409B2 (en) 2003-05-23 2009-08-11 Applied Biosystems, Llc Ionic liquid apparatus and method for biological samples
JP4669960B2 (ja) 2003-06-03 2011-04-13 株式会社 メドレックス 局所麻酔薬を含有する口中用または咽頭部用製剤
JP2005082512A (ja) 2003-09-05 2005-03-31 Medorekkusu:Kk イオン性の薬物の経皮吸収性を高めた外用剤
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
WO2005028446A1 (ja) 2003-09-18 2005-03-31 Sumitomo Chemical Company, Limited イオン性液体及びそれを使用する反応方法
KR20060093334A (ko) 2003-10-17 2006-08-24 가부시키가이샤 메드렉스 비구아니드계 약제를 함유하는 젤리 제제
US20050127319A1 (en) 2003-12-10 2005-06-16 Sanyo Chemical Industries, Ltd. Electrolytic solution for an electrochemical capacitor and an electrochemical capacitor using the same
CA2554389A1 (en) 2004-01-26 2005-08-11 University Of South Alabama Anionic-sweetener-based ionic liquids and methods of use thereof
ATE534405T1 (de) 2004-01-29 2011-12-15 Medrx Co Ltd Entzündungshemmendes analgetikum für die äussere anwendung
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
NZ550320A (en) 2004-04-15 2010-02-26 Chiasma Inc Compositions capable of facilitating penetration across a biological barrier
WO2007005470A2 (en) 2005-06-29 2007-01-11 Syngenta Participations Ag Liquid compositions for treating plant propagation materials
JP4750499B2 (ja) * 2005-08-01 2011-08-17 日華化学株式会社 イオン性液体並びにそれを用いた抗菌剤及び抗菌性繊維
CA2867194C (en) 2005-10-07 2016-10-04 The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
US20090264664A1 (en) 2005-10-21 2009-10-22 Medrx Co., Ltd. Preparation for external application comprising salt of mast cell degranulation inhibitor having carboxyl group with organic amine
JP5360751B2 (ja) 2007-01-29 2013-12-04 株式会社 メドレックス 非ステロイド系抗炎症薬と有機アミン化合物との塩とその用途
JP5190382B2 (ja) 2007-01-29 2013-04-24 株式会社 メドレックス 温度感受性物質製のマイクロニードルの製造方法
US8182557B2 (en) 2007-02-06 2012-05-22 North Carolina State University Use of lignocellulosics solvated in ionic liquids for production of biofuels
MX2009008940A (es) * 2007-02-26 2009-09-28 Dow Agrosciences Llc Derivados liquidos ionicos de acidos carboxilicos herbicidas y ciertas trialquilaminas o heteroarilaminas.
KR101546910B1 (ko) 2007-11-11 2015-08-25 가부시키가이샤 메드렉스 리도카인 테이프제
AU2008327436B2 (en) 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US8697096B2 (en) * 2007-12-11 2014-04-15 Medrx Co., Ltd. Tape preparation comprising etodolac in ionic liquid form
CA2619367A1 (en) 2008-01-29 2009-07-29 Medrx Co., Ltd. Gel preparation for oral administration
KR20100127300A (ko) 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물

Also Published As

Publication number Publication date
IL190646A (en) 2013-06-27
CN103271083A (zh) 2013-09-04
CN101326275B (zh) 2013-06-05
AU2012203353A1 (en) 2012-06-28
JP2014205720A (ja) 2014-10-30
US20070093462A1 (en) 2007-04-26
US20120264605A1 (en) 2012-10-18
JP5713534B2 (ja) 2015-05-07
CA2625004C (en) 2015-10-06
AU2012203353B2 (en) 2012-06-28
AU2012203353B9 (en) 2014-10-23
CA2867194C (en) 2016-10-04
CA2867194A1 (en) 2007-04-19
US8802596B2 (en) 2014-08-12
CA2625004A1 (en) 2007-04-19
IL190646A0 (en) 2008-12-29
AU2006302237C1 (en) 2012-11-08
EP1931760A4 (en) 2010-10-20
AU2006302237B2 (en) 2012-03-08
AU2006302237A1 (en) 2007-04-19
KR20080068679A (ko) 2008-07-23
EP1931760A2 (en) 2008-06-18
JP2012255022A (ja) 2012-12-27
KR20130114214A (ko) 2013-10-16
CN101326275A (zh) 2008-12-17
CN103271083B (zh) 2017-08-11
US8232265B2 (en) 2012-07-31
KR101592659B1 (ko) 2016-02-11
JP2009511497A (ja) 2009-03-19
MX343314B (es) 2016-11-01
WO2007044693A3 (en) 2007-08-23
WO2007044693A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
BRPI0616976A2 (pt) composições lìquidas iÈnicas multi-funcionais para superar polimorfismos e conferir propriedades a ingredientes ativos farmacêuticos, biológicos, nutricionais e energéticos
MY143795A (en) Tetrahydropyridoindole derivatives
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
DK1791532T3 (da) Sammensætning i mikropelletform med styret afgivelse af fysiologisk aktive stoffer, fremgangsmåde til deres fremstilling og anvendelse i den zootekniske sektor
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
MX2010003258A (es) Utilizacion de un nuevo agente natural en composiciones cosmeticas.
TW200621268A (en) Antimicrobial copolymers and uses thereof
CY1119968T1 (el) Συνθεσεις καινοτομων καλλυντικων και/ή φαρμακευτικων προϊοντων και χρησεις αυτων
TR201809592T4 (tr) Aktif içerik maddelerinin bileşimleri.
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
NO20075136L (no) Nye liposompreparater
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
MX2007012623A (es) Inulina de cadena larga.
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
TR200806298A2 (tr) Farmasötik formülasyon
BRPI0515860A (pt) derivados de tetralin e indano, e uso dos mesmos
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
UY28271A1 (es) Compuestos químicos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL